Today: 21 May 2026
Ondas Holdings (ONDS) stock jumps on rebrand plan — three dates traders are watching next
4 January 2026
2 mins read

Ondas Holdings (ONDS) stock jumps on rebrand plan — three dates traders are watching next

NEW YORK, January 4, 2026, 12:05 ET — Market closed

  • Ondas shares closed up 12.9% on Friday at $11.02 after the company outlined a planned name change and headquarters relocation.
  • A recent filing showed Ondas Networks extended the maturity of several notes to Jan. 15, pushing out near-term debt deadlines.
  • Investors head into Monday with another potential overhang: a scheduled share issuance tied to an earlier exchange transaction.

Ondas Holdings Inc (ONDS) shares ended Friday up 12.9% at $11.02, extending a sharp run in the small-cap defense technology name ahead of Monday’s reopening after the weekend.

The move matters now because the company is trying to reposition its corporate identity around what it describes as a scaled defense, security and industrial operating platform — a pitch that can broaden its investor base as autonomous systems become a more crowded theme trade.

It also comes as investors parse fresh SEC filings that touch on financing and liquidity, including a note maturity extension at a subsidiary that pushes a key repayment date into mid-January.

Ondas said on Friday it plans to change its corporate name to Ondas Inc. and has relocated its corporate headquarters to West Palm Beach, Florida. The company said the name change is expected to take effect in the first quarter and is not expected to disrupt operations, customer programs or delivery timelines.

“Renaming the Company to Ondas Inc. will better align our corporate identity with the operating platform we have built,” Chairman and CEO Eric Brock said in the company’s press release. Ondas Holdings Inc.

A Form 144 filing also showed director Ron Stern disclosed a proposed sale of 100,000 shares, and listed prior sales in recent months. Form 144 is a notice of a planned sale under Rule 144 and does not, by itself, confirm the trade was completed.

Friday’s jump came with heavy volume. Ondas traded between $9.91 and $11.06 and changed hands at about 136 million shares, well above its 20-day average volume of about 80 million, according to market data. Traders will be watching whether the stock can test the $11.70 level it last hit in October.

Ondas sells autonomous aerial and ground robotic systems through its Ondas Autonomous Systems unit and private wireless products through Ondas Networks, according to the company. Those markets put it alongside other defense- and drone-adjacent names that have seen rapid rotations in and out of favor with retail and momentum traders.

But the next catalyst also carries downside risk: a December filing said Ondas expects to issue about 2.39 million shares on Jan. 5 under exchange agreements linked to notes, warrants and shares at its Ondas Autonomous Systems subsidiary. The company also said it expects to record a one-time, non-cash charge of about $56.6 million in the fourth quarter as a result of the exchange. A non-cash charge is an accounting expense that does not use cash immediately, but it can still weigh on reported results.

Another near-term uncertainty is the Jan. 15 maturity date disclosed in a recent 8-K: Ondas Networks amended the maturity of multiple notes — including secured and convertible debt — to that date, a filing showed. The key question for equity holders is whether the company provides any further detail on repayment or additional extensions.

Macro risk appetite may also matter. The ISM Manufacturing PMI is due Monday, and the U.S. employment report for December is scheduled for Friday, Jan. 9, according to the Institute for Supply Management and the U.S. Bureau of Labor Statistics.

For Ondas, the market’s next checkpoints are Monday’s trading reaction to the rebrand and Florida headquarters move, the Jan. 5 share issuance, and any update ahead of the Jan. 15 note maturity.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
ASX Ltd stock today: shares cling to the low end of the 52-week range as 2026 opens quietly
Previous Story

ASX Ltd stock today: shares cling to the low end of the 52-week range as 2026 opens quietly

Tesco issues urgent “do not eat” recall for three pate lines after date-label error
Next Story

Tesco issues urgent “do not eat” recall for three pate lines after date-label error

Go toTop